Approval · Notice of Compliance 1686 · 2001
FOSAMAX: Notice of Compliance 1686
Issued April 9, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1686
- Date
- April 9, 2001
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: for use in the treatment of osteoporosis in men
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FOSAMAX | Not yet assigned | — |
Medicinal ingredients
- ALENDRONATE SODIUM 5 MG per TAB
- ALENDRONATE SODIUM 10 MG per TAB